GlassScriptPhysician profile
Nafeeza Alli
NPI 1588264246
$14,668.39
in general payments reported to CMS, 2019-2025
30 companies · $5,023 in 2025
The $5,023 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $1,374 · 2023: $4,113 · 2024: $3,950 · 2025: $5,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,085.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,552.17 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,406.09 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,262.39 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,161.44 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,115.09 | 2021-2025 | |
| Alkermes, INC. | $1,037.67 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $983.23 | 2021-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $942.68 | 2022-2025 | Auvelity |
| Indivior INC. | $770.00 | 2022-2025 | Sublocade, Perseris |
| Vanda Pharmaceuticals INC. | $769.16 | 2022-2025 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $647.03 | 2023-2025 | Trintellix |
| Bausch Health US, LLC | $553.45 | 2023-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $552.37 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Corium, LLC | $534.02 | 2022-2024 | Azstarys |
| Lundbeck LLC | $260.30 | 2022-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $257.06 | 2023-2024 | Quviviq |
| Braeburn INC. | $135.19 | 2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $119.87 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $117.67 | 2022 | |
| Collegium Pharmaceutical, INC. | $97.00 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $82.11 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $80.00 | 2023-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $50.86 | 2023 | Belsomra |
| Neos Therapeutics, LP | $34.70 | 2024 | Adzenys Xr-Odt |
| Luye Pharma (USA) LTD. | $33.94 | 2025 | Erzofri Extended-Release |
| Tempus Ai, INC | $28.67 | 2024 | |
| Astellas Pharma US INC | $25.03 | 2025 | Veozah |
| Acadia Pharmaceuticals INC | $23.38 | 2023 | Nuplazid |
| Tris Pharma INC | $20.84 | 2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $14.98 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nafeeza Alli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.